Security record · archived quarter
GLUE
Monte Rosa Therapeutics, Inc. · Healthcare · Biotechnology
7Tracked holders
—Δ holders
8.29MShares held
$30.99MReported value
+0New positions
−0Exits
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2024
Ownership over time
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 78 | -3 | 40.75M | $985.52M | +5 | −8 |
| Q1 2026 | 84 | +11 | 37.29M | $613.27M | +14 | −3 |
| Q4 2025 | 73 | -1 | 26.21M | $411.01M | +1 | −2 |
| Q3 2025 | 18 | +2 | 20.02M | $148.32M | +2 | — |
| Q2 2025 | 13 | +1 | 20.51M | $92.50M | +1 | — |
| Q1 2025 | 9 | -3 | 9.96M | $46.20M | +1 | −4 |
| Q4 2024 | 12 | +2 | 11.82M | $82.01M | +2 | — |
| Q3 2024 | 9 | +2 | 9.48M | $50.23M | +2 | — |
| Q2 2024 | 7 | — | 8.29M | $30.99M | — | — |
Who holds it · Q2 2024
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | T. Rowe Price ✦ | 5.98M | — | $22.36M | 0.0% | n/c | 1 | SEC ↗ |
| 2 | T. Rowe Price ✦ | 5.98M | — | $22.36M | 0.0% | n/c | 1 | SEC ↗ |
| 3 | Citadel Advisors ✦ | 995.94K | — | $3.72M | 0.0% | n/c | 1 | SEC ↗ |
| 4 | Citadel Advisors ✦ | 995.94K | — | $3.72M | 0.0% | n/c | 1 | SEC ↗ |
| 5 | Geode Capital Management ✦ (passive) | 847.44K | — | $3.17M | 0.0% | n/c | 1 | SEC ↗ |
| 6 | Geode Capital Management ✦ (passive) | 847.44K | — | $3.17M | 0.0% | n/c | 1 | SEC ↗ |
| 7 | Renaissance Technologies ✦ | 254.71K | — | $952,630 | 0.0% | n/c | 1 | SEC ↗ |
| 8 | Wellington Management ✦ | 166.67K | — | $623,350 | 0.0% | n/c | 1 | SEC ↗ |
| 9 | Wellington Management ✦ | 166.67K | — | $623,350 | 0.0% | n/c | 1 | SEC ↗ |
| 10 | D. E. Shaw & Co. ✦ | 23.42K | — | $87,598 | 0.0% | n/c | 1 | SEC ↗ |
| 11 | Millennium Management ✦ | 20.93K | — | $78,271 | 0.0% | n/c | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 188 holders, 86.88M shares, $1.31B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
Frequently co-owned
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Provenance: Ownership from parsed 13F common-stock positions (tracked universe, comparable sets for changes); insider rows from Forms 3/4/5; stakes from Schedules 13D/13G; every filing links to its original on SEC EDGAR.
Reporting period: Q2 2024 ·
Methodology ·
Get this via the API